



## Sukmook Lee

Visiting Professor, Neurosurgery

---

### Bio

#### BIO

Professor Sukmook Lee, Ph.D., is a distinguished expert in the field of antibody engineering and therapeutic antibody development. He currently serves as the Director of the Antibody Research Institute and Professor in the Department of Biopharmaceutical Chemistry at Kookmin University. Additionally, he holds a Visiting Professorship in the Department of Neurosurgery at Stanford University School of Medicine. His cutting-edge research is globally recognized, particularly for its focus on immunological disorders, infectious diseases, and cancer therapies.

As the head of the Innovative Antibodies Laboratory (InnoAbs), a globally leading research group, Professor Lee spearheads pioneering efforts to develop novel therapeutic antibodies. His lab's work has made significant strides in cancer immunotherapy, COVID-19 treatment, and the creation of diagnostic antibodies for COVID-19. The InnoAbs Lab also collaborates extensively with academic and industrial partners to drive innovation in therapeutic targeting, cancer progression, and metastasis.

Professor Lee is widely recognized in the scientific community, serving on the editorial boards of high-impact journals such as Scientific Reports, Antibodies, and Frontiers in Bioscience. He also contributes as a bio-advisory board member for leading pharmaceutical companies, including Samsung Biologics, Samsung Bioepis, ISU Abxis, and Ankook Pharmaceutical. His extensive consulting work for both international and domestic industries highlights his pivotal role in bridging academic research with practical medical applications. In addition, he serves as a steering committee member for the Korean Society for Biochemistry and Molecular Biology (KSBMB) and the Antibody Society of Korea (ASK), and is an active member of The Antibody Society and the American Association for Cancer Research (AACR) in the USA.

A visionary researcher, Professor Lee continues to push the boundaries of modern medicine, particularly through his efforts to commercialize groundbreaking antibody platforms for cancer and viral therapies, bringing new hope to patients worldwide.